FDA report sheds light on mislabeled products

A recent report from the FDA that tracked the cannabinoid content of CBD products over the past six years shows nearly half of all products tested were mislabeled.

The products tested ran the gamut from oils to capsules, gummies, topicals, conventional food items and pet treats, among others. Two products were referred to the Drug Enforcement Agency after lab analysis revealed that one product, a CBD oil capsule, contained 16 mg/g of THC and another, a CBD gummy, tested positive for a synthetic cannabinoid. 

The FDA took into account several factors when choosing which products to test, but most prominent, were products that made “serious disease claims,” the report notes. 


Leave a Reply